CDMO Samsung Biologics has quickly established itself as one of the most ambitious and successful contract manufacturing organizations over the last year.
But what’s next for this fast-moving contract manufacturing organization, and what are the implications for the biotech industry, healthcare, and the planet? Here’s our rundown of what’s coming down the pipeline for Samsung Biologics.
Increased Emphasis on Sustainability
In the first quarter of 2021, CDMO Samsung Biologics officially launched an ESG committee, designed to oversee the creation and supervision of policies at the managerial level that would help ensure eco-friendly practices at the company.
The committee includes four directors from various fields who will closely monitor the eco-friendly and sustainable practices of Samsung Biologics at all times.
Samsung Biologics recently garnered notice as being one of the largest contract manufacturing organizations to obtain ISO Certification for Energy Management and Occupational Health and Safety Management.
Samsung Biologics also announced that they plan to install solar panels and generators as well as sustainably functioning refrigerants in their manufacturing plants.
Samsung Group Investment
Perhaps one of the most promising announcements relating to the future of Samsung Biologics came from the organization’s parent company, Samsung Group. In August it was announced that Samsung Group would be investing an astounding $205 billion in its biopharmaceutical, semiconductor, and telecommunications businesses to help prepare for the ‘post-COVID-19 era.’
A large part of the investment will reportedly go toward new hires, with Samsung planning to recruit over 40,000 new employees.
Additionally, it was announced that this investment will go toward funding not one but two additional Samsung Biologics plants at its headquarters in Incheon, South Korea. This is in addition to the already in-constructionPlant 4, which upon completion will be the largest single-site manufacturing capacity on the planet.
Expansion of mRNA Capabilities
As mRNA-based solutions become more widely used, Samsung Biologics is further expanding itsmRNA drug substance manufacturing capabilities with facility additions, increased investments, and R&D.
James Choi, Senior VP of Samsung Biologics, had this to say in a recent interview:
“As part of our long-term growth strategy to serve the varying needs of our clients and the biopharma industry, we’ve been expanding our business portfolio and production capacity to meet the growing demand in mRNA manufacturing services. Apart from the agreement in late May this year for the aseptic fill-finish as well as packaging and labeling of Moderna’s COVID-19 mRNA vaccine, we recently announced plans to add an mRNA drug substance suite to our site by the first half of 2022 to diversify our service offerings. We see great potential for mRNA technology to address a broader range of diseases, beyond COVID-19.”
He went on to note that despite the high barrier of entry and initial investment required for managing mRNA production, he feels that Samsung Biologics’ team of experts is prepared to be fully operational for mRNA vaccine production by early 2022.
Plant 4 and the New R&D Center
In their Q2 2021 report, Samsung Biologics announced that construction of their landmark Plant 4 was still on schedule, expected to commence partial operation by the conclusion of 2022 and full operation by early 2023. When complete, it will possess the largest single-site manufacturing capacity on the planet.
Meanwhile, the San Francisco R&D center announced last year is now fully equipped for ‘high-quality cell line development in support of client pipelines in close proximity to the U.S. market.’